Thomas Eastling

Thomas Wilson Eastling is currently Director at Shanghai Genomics, Inc. since 2015.
Mr. Eastling is Chief Financial Officer, Secretary & Director at Berkeley Advanced Biomaterials, Inc. since 2017.
Mr. Eastling is Director at GNI Group Ltd. since 2021.
Mr. Eastling is Non-Executive Director at Continent Pharmaceutical, Inc. since 2015.
Mr. Eastling is Director at GNI Hong Kong Ltd. since 2015.
Mr. Eastling is Chief Financial Officer & Director at Cullgen, Inc. since 2018.
Mr. Eastling is Director at Shanghai GEP Pharmaceuticals, Inc. since 2018.
Mr. Eastling is a Member of the National Association of Corporate Directors.
Mr. Eastling is Chief Financial Officer & Secretary at GNI USA, Inc. since 2015.
Mr. Eastling is Chief Financial Officer & Head-Investor Relations at Cullgen, Inc. (New).
Mr. Eastling is Chief Financial Officer at Gyre Therapeutics, Inc. starting 2023.
Former positions include Managing Director & Senior Vice President-Japan at Duff & Phelps Credit Rating Co. from 1999 to 2000.
Mr. Eastling was Managing Director at Fitch Group, Inc. Mr. Eastling was Director at Catalyst Biosciences, Inc. Mr. Eastling was Independent Director at Kai Wo Asset Management Ltd. Mr. Eastling was MD-Strategic Planning & Investor Relations at SoftBank Corp.
from 2001 to 2003.
Education includes a graduate degree from Thunderbird School of Global Management conferred in 1983 and an undergraduate degree from the University of Southern California conferred in 1981.